Olivier Chambenoit - Concepedia

Author

Olivier Chambenoit

Novartis (United States)

Also Known As

O Chambenoit, O. Chambenoit, OLIVIER CHAMBENOIT, Oliver Chambenoit, Olivier Chambenoit

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Inserm Centre National de la Recherche Scientifique University of Toronto Centre d’Immunologie de Marseille-Luminy

About

Olivier Chambenoit is an author at Novartis (United States) specializing in medicine, cellular biochemistry, and cellular physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.1K
2	Allergy	2	2	516
3	Natural Sciences	1	1	74
4	Public Health	1	1	10
5	Allergy Medicine	1	1	38

Olivier Chambenoit

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Yannick Hamon, Cyril Broccardo, Olivier Chambenoit, Nature Cell Biology Signal TransductionMedicineApoptosisCell DeathProtein Phosphorylation	2000	523
Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice Evelyn Orsó, Cyril Broccardo, Wolfgang E. Kaminski, Nature Genetics AllergyMembrane TransportAbc1-deficient MiceTangier Disease PatientsProtein Transport	2000	478
Specific Docking of Apolipoprotein A-I at the Cell Surface Requires a Functional ABCA1 Transporter Olivier Chambenoit, Yannick Hamon, Didier Marguet, Journal of Biological Chemistry	2001	206
Distinct sites on ABCA1 control distinct steps required for cellular release of phospholipids Véronique Rigot, Yannick Hamon, Olivier Chambenoit, Journal of Lipid Research Proteinlipid InteractionSignal TransductionBiochemistryMedicineAbca1-dependent Events	2002	74
Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database Kurt Oelke, Olivier Chambenoit, Amar Q Majjhoo, Journal of Comparative Effectiveness Research	2019	51
Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial Gordon Sussman, Jacques Hébert, Wayne Gulliver, The Journal of Allergy and Clinical Immunology In Practice AllergyAllergy MedicineClinical TrialsOptima TrialClinical Dermatology	2020	38
Construction and functional screening of a metagenomic library using a T7 RNA polymerase-based expression cosmid vector François-Xavier Lussier, Olivier Chambenoit, Amélie Côté, Journal of Industrial Microbiology & Biotechnology	2010	24
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients Ana‐Maria Orbai, Iain B. McInnes, Laura C. Coates, The Journal of Rheumatology	2019	19
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study Tien N. Nguyen, Melvin Churchill, Robert M. Levin, The Journal of Rheumatology	2022	15
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies Ana‐Maria Orbai, M. Elaine Husni, Dafna D. Gladman, Rheumatology and Therapy	2021	11

Page 1